(Updated - April 13, 2026 4:21 PM EDT)

Raymond James analyst Martin Auster initiates coverage on Spyre (NASDAQ: SYRE) with a Strong Buy rating and a price target of $80.00.

The analyst commented, "We are initiating coverage of Spyre Therapeutics (SYRE) at Strong Buy with an $80 price target. Spyre is developing next-generation, long-acting antibodies for validated targets, including α4β7, TL1A, and IL-23. We believe SYRE is uniquely positioned to capitalize on (1) the combination therapy opportunity in IBD and (2) TL1A expansion into rheumatic diseases, with shares offering a highly compelling risk-reward skew into a slew of PoC data readouts in 2026/2027."

For an analyst ratings summary and ratings history on Spyre click here. For more ratings news on Spyre click here.

Shares of Spyre closed at $51.29 yesterday.

Analyst Comments New Coverage